Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.

Cancer immunology, immunotherapy : CII - 1 Dec 2021

Chen Xi, Fang Liangjie, Zhu Yanping, Bao Zhang, Wang Qing, Liu Rong, Sun Wenjia, Du Haiwei, Lin Jing, Yu Bing, Chen Songan, Zhou Jianya, Zhou Jianying

Abstract excerpt

BACKGROUND: Tissue tumor mutation burden (tTMB) assessed by whole-exome sequencing (WES), which has been regarded as the gold standard method of tTMB measurement, can predict the clinical benefits of immune checkpoint inhibitors (ICIs). Multiple studies have investigated the feasibility of utilizing large panels to evaluate TMB but have obtained conflicting results. Furthermore, whether blood TMB (bTMB) can also...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Cohort Studies

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Mutation

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 33899131
DOI: 10.1007/s00262-021-02943-2
PMCID: PMC10991091

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.PMID 33899131Read ↗

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene PanelSemantic proximity Read ↗

Evaluation of Prognostic Utility of Tumor Mutation Burden for NSCLC response to Immune Checkpoint Blockade Therapy: A Single Institute StudySemantic proximity Read ↗

Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.Semantic proximity Read ↗

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.Semantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current EvidenceSemantic proximity Read ↗

Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real‐life analysis of three larger gene panelsSemantic proximity Read ↗

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung CancerSemantic proximity Read ↗

Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report.Semantic proximity Read ↗

Estimating tumor mutational burden across multiple cancer types using whole-exome sequencingSemantic proximity Read ↗

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.Semantic proximity Read ↗

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.